Foreign media analysis says October nonfarm payrolls will further confirm the Fed’s view that labor-market fundamentals remain solid, allowing officials to keep attention on curbing inflation, which has accelerated this year. Unless financial markets suffer a large-scale sell-off severe enough to begin weighing on growth, the Fed is likely to continue raising rates.

China's National Medical Products Administration approved Beijing Yimiao Shenzhou Biopharmaceutical Co. Ltd.'s polatuzumab vedotin injection, marketed as Saibohua, for adults with relapsed or refractory large B‑cell lymphoma after two or more lines of systemic therapy, including diffuse large B‑cell lymphoma (not otherwise specified), grade 3b follicular lymphoma and high‑grade B‑cell lymphoma. The approval provides a new treatment option for these patient groups.

South Korea's finance minister said Seoul will implement its trade agreement with the United States and step up engagement with the US Congress and state governments.